Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Affimed subsidiary raises $14M, unveils Janssen deal

Affimed Therapeutics AG (Heidelberg, Germany) said its U.S. subsidiary Amphivena Therapeutics

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE